Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.85
IGXT's Cash to Debt is ranked lower than
71% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. IGXT: 1.85 )
Ranked among companies with meaningful Cash to Debt only.
IGXT' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: N/A Max: No Debt
Current: 1.85
Equity to Asset 0.36
IGXT's Equity to Asset is ranked lower than
81% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IGXT: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
IGXT' s Equity to Asset Range Over the Past 10 Years
Min: -0.4  Med: 0.69 Max: 0.9
Current: 0.36
-0.4
0.9
F-Score: 3
Z-Score: 2.09
M-Score: -5.03
WACC vs ROIC
6.27%
-26.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -23.51
IGXT's Operating margin (%) is ranked higher than
63% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. IGXT: -23.51 )
Ranked among companies with meaningful Operating margin (%) only.
IGXT' s Operating margin (%) Range Over the Past 10 Years
Min: -555.91  Med: -180.77 Max: 27.2
Current: -23.51
-555.91
27.2
Net-margin (%) -26.79
IGXT's Net-margin (%) is ranked higher than
60% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. IGXT: -26.79 )
Ranked among companies with meaningful Net-margin (%) only.
IGXT' s Net-margin (%) Range Over the Past 10 Years
Min: -557.27  Med: -180.35 Max: 25.34
Current: -26.79
-557.27
25.34
ROE (%) -26.01
IGXT's ROE (%) is ranked higher than
55% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. IGXT: -26.01 )
Ranked among companies with meaningful ROE (%) only.
IGXT' s ROE (%) Range Over the Past 10 Years
Min: -1461.46  Med: -128.88 Max: 25.47
Current: -26.01
-1461.46
25.47
ROA (%) -13.96
IGXT's ROA (%) is ranked higher than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. IGXT: -13.96 )
Ranked among companies with meaningful ROA (%) only.
IGXT' s ROA (%) Range Over the Past 10 Years
Min: -193.99  Med: -81.61 Max: 16.99
Current: -13.96
-193.99
16.99
ROC (Joel Greenblatt) (%) -23.11
IGXT's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. IGXT: -23.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IGXT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -808.25  Med: -311.27 Max: 54.17
Current: -23.11
-808.25
54.17
Revenue Growth (3Y)(%) 44.20
IGXT's Revenue Growth (3Y)(%) is ranked higher than
87% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. IGXT: 44.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IGXT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -15.95 Max: 192.4
Current: 44.2
0
192.4
GuruFocus has detected 9 Warning Signs with Intelgenx Technologies Corp $IGXT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IGXT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:GLMD, NAS:BLRX, OTCPK:COTQF, NAS:BCLI, NAS:KMPH, NAS:APVO, NAS:OCRX, NAS:CYTR, NAS:CHMA, NAS:ADHD, AMEX:PLX, NAS:CAPR, NAS:ITEK, NAS:EBIO, NAS:PBMD, NAS:AVEO, NAS:AVIR, NAS:CBAY, NAS:CUR, OTCPK:QBIO » details
Traded in other countries:IGX.Canada, 0IL.Germany,
Intelgenx Technologies Corp., is a drug delivery company. The Company is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.

Intelgenx Technologies Corp., was incorporated in Delaware on July 27, 1999. The Company is a drug delivery company. It is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies. Its product development efforts are based upon three platform technologies: Versafilm- an oral film technology, VersaTab- a multilayer tablet technology and AdVersa- a mucoadhesive tablet technology. The Oral Film technology consists of a thin (25-35 micron) polymeric film comprised of United States Pharmacopeia (USP) components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Its multilayer tablet technology allows for the development of oral controlled-release products. The mucoadhesive tablet is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site of application at a controlled rate. The Company's product portfolio includes a blend of generic and branded products based on its proprietary delivery technology. Some of its products are INT0001/2004, INT0004/2006, INT0007/2006, and among others. The Company competes with pharmaceutical industries. Some of its competitors include Monosol Rx, Tesa-Labtec GmbH, BioDelivery Sciences International, Inc and LTS Lohmann Therapy Systems Corp. It is subject to change in governmental regulations, healthcare legislations, availability of financing, patent litigation and other factors.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 37.74
IGXT's Price/Owner Earnings (ttm) is ranked lower than
59% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.43 vs. IGXT: 37.74 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
IGXT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 26.36  Med: 34.55 Max: 42.27
Current: 37.74
26.36
42.27
P/B 11.08
IGXT's P/B is ranked lower than
87% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. IGXT: 11.08 )
Ranked among companies with meaningful P/B only.
IGXT' s P/B Range Over the Past 10 Years
Min: 4.66  Med: 10.14 Max: 90
Current: 11.08
4.66
90
P/S 11.86
IGXT's P/S is ranked lower than
52% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. IGXT: 11.86 )
Ranked among companies with meaningful P/S only.
IGXT' s P/S Range Over the Past 10 Years
Min: 4.9  Med: 15.38 Max: 97.14
Current: 11.86
4.9
97.14
POCF 21.26
IGXT's POCF is ranked lower than
54% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 21.07 vs. IGXT: 21.26 )
Ranked among companies with meaningful POCF only.
IGXT' s POCF Range Over the Past 10 Years
Min: 14.87  Med: 39.23 Max: 58.89
Current: 21.26
14.87
58.89
EV-to-EBIT -41.62
IGXT's EV-to-EBIT is ranked lower than
99.99% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. IGXT: -41.62 )
Ranked among companies with meaningful EV-to-EBIT only.
IGXT' s EV-to-EBIT Range Over the Past 10 Years
Min: -58.7  Med: -12.3 Max: 375.1
Current: -41.62
-58.7
375.1
EV-to-EBITDA -73.24
IGXT's EV-to-EBITDA is ranked lower than
99.99% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. IGXT: -73.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
IGXT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -103.3  Med: -12.6 Max: 116.6
Current: -73.24
-103.3
116.6
Current Ratio 1.10
IGXT's Current Ratio is ranked lower than
86% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. IGXT: 1.10 )
Ranked among companies with meaningful Current Ratio only.
IGXT' s Current Ratio Range Over the Past 10 Years
Min: 0.66  Med: 4.16 Max: 11.6
Current: 1.1
0.66
11.6
Quick Ratio 1.10
IGXT's Quick Ratio is ranked lower than
82% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. IGXT: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
IGXT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 4.16 Max: 11.6
Current: 1.1
0.66
11.6
Days Sales Outstanding 16.01
IGXT's Days Sales Outstanding is ranked higher than
83% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. IGXT: 16.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGXT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.01  Med: 159.91 Max: 390.59
Current: 16.01
16.01
390.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.40
IGXT's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. IGXT: -8.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IGXT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -120.3  Med: -27.95 Max: -8.4
Current: -8.4
-120.3
-8.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.50
IGXT's Price/Tangible Book is ranked lower than
81% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. IGXT: 10.50 )
Ranked among companies with meaningful Price/Tangible Book only.
IGXT' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.25  Med: 10 Max: 75
Current: 10.5
5.25
75
Price/Median PS Value 0.78
IGXT's Price/Median PS Value is ranked higher than
65% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. IGXT: 0.78 )
Ranked among companies with meaningful Price/Median PS Value only.
IGXT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.4  Med: 1 Max: 5.64
Current: 0.78
0.4
5.64
Earnings Yield (Greenblatt) (%) -2.36
IGXT's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. IGXT: -2.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IGXT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.48  Med: 2.35 Max: 5.1
Current: -2.36
-2.48
5.1

More Statistics

Revenue (TTM) (Mil) $4.81
Beta0.63
Short Percentage of Float0.00%
52-Week Range $0.37 - 1.00
Shares Outstanding (Mil)64.67

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 6 7 8 17
EPS ($) -0.01 -0.02 -0.03 0.04
EPS w/o NRI ($) -0.01 -0.02 -0.03 0.04
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for IGXT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
IntelGenx Grants Stock Options Jan 19 2017
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Jan 04 2017
IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet Jan 04 2017
IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet Jan 04 2017
IntelGenx Announces Development and Commercialization Agreement with Endo Ventures Dec 27 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Dec 27 2016
IntelGenx Announces Development and Commercialization Agreement with Endo Ventures Dec 27 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Dec 14 2016
RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT®... Dec 14 2016
RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT®... Dec 14 2016
IntelGenx and RedHill Biopharma Announce Definitive Agreement for Commercialization of RIZAPORT(R)... Dec 14 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Dec 01 2016
IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an... Dec 01 2016
IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an... Dec 01 2016
IntelGenx Technologies Corp. :IGXT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29,... Nov 29 2016
IntelGenx Secures a License For Tadalafil Erectile Dysfunction Dosing Patent Nov 21 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Nov 21 2016
IntelGenx Secures a License For Tadalafil Erectile Dysfunction Dosing Patent Nov 21 2016
INTELGENX TECHNOLOGIES CORP. Financials Nov 18 2016
IntelGenx Reports Profitable Third Quarter with Increased Growth in Revenues from Second Quarter Nov 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)